Skip to main content

Security report for aurobindo.com

Aurobindo Pharma Limited · Healthcare · India

Medium risk. 2 critical or high findings in GDPR outside view and SSL/TLS.

Security score

63/100

Risk levelMedium

0–100, higher is better. How it is calculated

Aurobindo Pharma Limited is a leading global pharmaceutical company specializing in generic drugs, biosimilars, and active pharmaceutical ingredients. With a significant manufacturing footprint and a strong R&D pipeline, the company serves over 150 global markets including the US and Europe. The website reflects a mature digital presence with comprehensive business, investor, and sustainability information. Technically, the site uses modern frameworks such as Next.js and Bootstrap, ensuring good performance and mobile optimization. Security posture is adequate with HTTPS and cookie consent mechanisms, though there is room for improvement in security headers and explicit policies. Overall, the website is professional, trustworthy, and well-aligned with the company's business stature.

Scanned

NIS2 and GDPR posture

GDPR outside view
58/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • Critical

      No HTTPS encryption

      GDPR requires appropriate security measures for personal data

      What to do: Implement SSL/TLS certificate for HTTPS

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • Critical

      No HTTPS Encryption

      Website does not use HTTPS encryption, making all data transmission vulnerable to interception

      What to do: Implement SSL/TLS certificate and redirect all HTTP traffic to HTTPS

Need hands-on remediation? Email guard@offseq.com

Keep watching aurobindo.com

This scan found 17 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
0
Security headers
80
Email security
70
DNS health
70
Network security
100
GDPR outside view
58
Average
63

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The company holds a strong market position as one of the largest generic pharmaceutical companies in the US and a top 10 player in Europe. Its business model focuses on affordable medicines with a broad portfolio and global reach. The presence of subsidiaries specializing in biosimilars and specialty products indicates diversification and growth orientation. Investor relations and sustainability reporting demonstrate transparency and corporate governance maturity. The target audience includes healthcare providers, investors, and global pharmaceutical markets.

Security posture

The website employs HTTPS and a cookie consent banner, indicating baseline security and privacy compliance. However, the absence of explicit security policies, incident response contacts, and security headers suggests moderate security maturity. No vulnerabilities or exposed sensitive data were detected in the HTML content. The company should enhance its security posture by publishing clear security policies, implementing security headers, and establishing incident response communication channels.

Recommendations

  1. Implement comprehensive security headers such as Content-Security-Policy and X-Frame-Options.
  2. Publish explicit security and incident response policies on the website.
  3. Add contact information for security incidents (e.g., security@ or abuse@ emails).
  4. Improve accessibility compliance to meet standards such as WCAG.
  5. Enhance privacy disclosures with data retention policies and DPO contact details.

Contact details published on the site

Addresses
Legal name
Aurobindo Pharma Limited
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Aurobindo Pharma Limited
Description
Aurobindo Pharma Limited is a global pharmaceutical company committed to making medicines affordable and accessible worldwide. It operates 29 manufacturing facilities with capacities exceeding 50 billion formulation units and 19,000+ MT APIs. The company has a strong R&D focus with 830 US ANDA filings and 600+ approvals. It serves over 150 global markets including the US, Europe, and growth markets, ranking among the top 10 generic companies in eight European countries.
Key services
Generic pharmaceuticals, Biosimilars, Active Pharmaceutical Ingredients (APIs), Specialty pharmaceutical products
Content quality
excellent
Branding
consistent

Technology

Stack
React, Next.js, Bootstrap, jQuery, Swiper, Isotope, Popper.js, Ionicons
Frameworks
Next.js, Bootstrap
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
75/100
Good practices seen
  • HTTPS enabled
  • Cookie consent banner implemented

Analytics and tracking

Services
Google Tag Manager
Tracking level
moderate
Privacy practices
basic

Advertising

Transparency
basic

Site quality

Design
excellent
User experience
good
Content relevance
excellent
Navigation
good
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is professionally designed with comprehensive business and investor information.
  2. Strong presence of pharmaceutical industry content including manufacturing, R&D, and sustainability.
  3. Social media integration with LinkedIn and Twitter official accounts.
  4. Cookie consent mechanism is implemented and visible.
  5. No explicit terms of service page found.
  6. No visible security or incident response policies on the website.
  7. No exposed sensitive data or obvious vulnerabilities detected in the HTML content.
  8. Use of modern web technologies and frameworks.
  9. No WAF or blocking detected; site fully accessible.
Technical notes

Notes

The website is built on a modern React/Next.js framework with Bootstrap for responsive design. It uses common JavaScript libraries like jQuery and Swiper for UI interactions. Performance is moderate with preloading of fonts and scripts. SEO is supported by meta tags and structured navigation. The site is mobile optimized and accessible with basic features. There is no detected CMS, indicating a custom or proprietary platform. Hosting provider details are not evident from the HTML content.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with aurobindo.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review aurobindo.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.